SB-715992 In Combination With Docetaxel In Patients With Solid Tumors

GlaxoSmithKline30 enrolled

Overview

The purpose of this study is to determine the dose regimen of SB-715992 in combination with docetaxel in patients with solid tumors. SB-715992 and docetaxel were dosed by 1-hour intravenous infusion every 3 weeks (on the same day). A patient may continue to receive treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of both drugs in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment with SB-715992. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Solid Tumor Cancer

Interventions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion criteria: * Histologically or cytologically confirmed diagnosis of an advanced solid tumor malignancy that is not responsive to standard therapies or for which there is no standard therapy. * ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2. Exclusion criteria: * Females who are pregnant or nursing. * Pre-existing hemolytic anemia. * Pre-existing peripheral neuropathy greater than or equal grade 2. Greater than or equal to 4 prior chemotherapy regimens including neoadjuvant/adjuvant chemotherapy, except breast cancer subjects who may have received more than 4 prior chemotherapy regimens. * Absolute neutrophil count less than 1,500/mm3. * Platelets less than 100,000/mm3. * Hemoglobin less than 9 g/dL. * Total bilirubin greater than1.5 mg/dL. * AST/ALT greater than 2.5 X upper limit of normal. * Creatinine clearance less than or equal to 60 mL/min (calculated by the Cockcroft Gault Formula). * Known contraindications to the use of docetaxel or to other drugs formulated with polysorbate 80.

Locations (2)

GSK Investigational Site

Oxford, Oxfordshire, United Kingdom

GSK Investigational Site

London, United Kingdom

Outcomes

Primary Outcomes

Safety and tolerability endpoints will consist of the valuation of adverse events (AEs),vital signs and laboratory values. A dose regimen where 1 of 6 (or 17%) subjects experience a dose-limiting toxicity.

Time frame: throughout the study

Secondary Outcomes

PK endpoints of SB-715992 and docetaxel pending the conduct of the PK interaction portion. Antitumor activity will be assessed every 2 cycles (PD).

Time frame: every 2 cycles